EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma

Mohanraj Ramachandran, Alessandra Vaccaro, Tiarne van de Walle, Maria Georganaki, Roberta Lugano, Kalyani Vemuri, Despoina Kourougkiaouri, Konstantinos Vazaios, Marie Hedlund, Georgia Tsaridou, Lene Uhrbom, Ilkka Pietilä und 8 weitere

Cancer Cell · 2023-06 · 41 (6) · 1134-1151.e10

DOI: 10.1016/j.ccell.2023.04.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-06. Verfasst von Mohanraj Ramachandran und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala Universitet, Cancerfonden, Science for Life Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T cell infiltration. LIGHT/TNFSF14 can induce high endothelial venules (HEVs) and tertiary lymphoid structures (TLS), suggesting that its therapeutic expression could promote T cell recruitment. Here, we use a brain endothelial cell-targeted adeno-associated viral (AAV) vector to express LIGHT in the glioma vasculature (AAV-LIGHT). We found that systemic AAV-LIGHT treatment induces tumor-associated HEVs and T cell-rich TLS, prolonging survival in αPD-1-resistant murine glioma. AAV-LIGHT treatment reduces T cell exhaustion and promotes TCF1+CD8+ stem-like T cells, which reside in TLS and intratumoral antigen-presenting niches. Tumor regression upon AAV-LIGHT therapy correlates with tumor-specific cytotoxic/memory T cell responses. Our work reveals that altering vascular phenotype through vessel-targeted expression of LIGHT promotes efficient anti-tumor T cell responses and prolongs survival in glioma. These findings have broader implications for treatment of other immunotherapy-resistant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsGlioblastomaMiceAnimalsPhenotypeBrainTumor Microenvironment

Stichwörter der Autor:innen

LIGHTTNFSF14antigen-presenting nichesglioblastomahigh endothelial venuleslymphotoxin αβstem-like T cellstertiary lymphoid structures

Autor:innen und Institutionen

  • Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden.
  • Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, 41345 Gothe…
  • Department of Neurosurgery, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530…
  • Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden. Electronic address: magnus.essand@igp.uu.se.
  • Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden. Electronic address: anna.dimberg@igp.uu.se.

Förderung

  • Uppsala Universitet
  • Cancerfonden
  • Science for Life Laboratory
  • Hjärnfonden
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • Barncancerfonden

Zitieren

APA

Ramachandran, M., Vaccaro, A., van de Walle, T., Georganaki, M., Lugano, R., Vemuri, K., Kourougkiaouri, D., Vazaios, K., Hedlund, M., Tsaridou, G., Uhrbom, L., Pietilä, I., Martikainen, M., van Hooren, L., Olsson Bontell, T., Jakola, A. S., Yu, D., Westermark, B., Essand, M., & Dimberg, A. (2023). Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41(6), 1134-1151.e10. https://doi.org/10.1016/j.ccell.2023.04.010

Vancouver

Ramachandran M, Vaccaro A, van de Walle T, Georganaki M, Lugano R, Vemuri K, et al. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell. 2023;41(6):1134-1151.e10. doi:10.1016/j.ccell.2023.04.010

BibTeX
@article{Ramachandran2023,
  author = {Ramachandran, Mohanraj and Vaccaro, Alessandra and van de Walle, Tiarne and Georganaki, Maria and Lugano, Roberta and Vemuri, Kalyani and Kourougkiaouri, Despoina and Vazaios, Konstantinos and Hedlund, Marie and Tsaridou, Georgia and Uhrbom, Lene and Pietilä, Ilkka and Martikainen, Miika and van Hooren, Luuk and Olsson Bontell, Thomas and Jakola, Asgeir S and Yu, Di and Westermark, Bengt and Essand, Magnus and Dimberg, Anna},
  title = {Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {6},
  pages = {1134--1151.e10},
  doi = {10.1016/j.ccell.2023.04.010}
}
Kostenlos starten →